The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.
 
Eva Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Roche
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Tomás Pascual
Honoraria - Argenetics; AstraZeneca; Lilly; Novartis; Veracyte
Consulting or Advisory Role - Novartis; Roche/Genentech
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Veracyte
 
Guillermo Villacampa
Honoraria - Reveal Genomics
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Speakers' Bureau - MSD Oncology; Pfizer; Pierre Fabre
 
Sonia Pernas
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Pfizer; Pierre Fabre; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - SOLTI
 
Rodrigo Sanchez-Bayona
Honoraria - AstraZeneca; GlaxoSmithKline; Lilly; Novartis; Seagen
Consulting or Advisory Role - GlaxoSmithKline; Lilly; Novartis
Speakers' Bureau - AstraZeneca; Novartis
Expert Testimony - AstraZeneca; Novartis
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
 
Jose Juan Ponce-Lorenzo
Honoraria - Agendia; AstraZeneca/Daiichi Sankyo; Gilead Sciences; Lilly; Novartis; Pfizer; Seagen
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Novartis; Pierre Fabré; Seagen
 
Blanca Cantos Sanchez de Ibarguren
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Eisai; Gilead Sciences; Gilead Sciences; Lilly; Novartis; Pfizer
Speakers' Bureau - Daiichi Sankyo Europe GmbH
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Pfizer
 
Santiago Escrivá-de-Romaní
Consulting or Advisory Role - Cor2Ed; Daiichi Sankyo/Astra Zeneca; Jazz Pharmaceuticals; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Cor2Ed; Daiichi Sankyo/Astra Zeneca; Novartis; Pfizer; Seagen
Research Funding - Byondis (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Jazz Pharmaceuticals (Inst); medsir (Inst); Roche (Inst); SOLTI (Inst); Synthon (Inst); Zymeworks (Inst)
Expert Testimony - Cor2Ed
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Kern Pharma; Pfizer; Seagen; SOLTI
 
Antonia Perello
No Relationships to Disclose
 
Alvaro Montaño
No Relationships to Disclose
 
Eduardo Martinez
No Relationships to Disclose
 
Ana López González
No Relationships to Disclose
 
Mireia Melé Olivé
No Relationships to Disclose
 
Juan De La Haba
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics
 
Mafalda Oliveira
Honoraria - AstraZeneca; Eisai Europe; Gilead Sciences; Lilly; Medscape; Pfizer; Roche; SeaGen
Consulting or Advisory Role - AstraZeneca; Cureo Science; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; iOne; ITeos Therapeutics; Lilly; MSD; Pfizer; Relay Therapeutics; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Eisai; Gilead Sciences; Pierre Fabre
(OPTIONAL) Uncompensated Relationships - Head of the SOLTI Breast Cancer Research Group
 
Lorea Villanueva
Patents, Royalties, Other Intellectual Property - CIMA, Pamplona, Spain PCT/EP2018/055409 New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells (Inst); IJC, Barcelona, Spain PCT / EP2022 / 054803 MARKERS OF PREDICTION OF RESPONSE TO CAR T CELL THERAPY (Inst)
 
Xavier Gonzalez
Expert Testimony - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - AstraZeneca
 
Patricia Villagrasa
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Oncolytics; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc